Inscripta (formerly known as Muse Biotechnology) was founded in 2015 by Andrew Garst, Ryan Gill, and Tanya Lipscomb. Following a 2021 funding round, a company spokesperson told reporters that Inscripta has no plans to go public in the near future.

Inscripta is the developer of a genomic engineering platform. Genomic engineering, more commonly known as "gene editing," is the process by which scientists can modify the genetic blueprint of a living organism. Researchers have used the process to modify yeast cells so that the organisms will produce useful byproducts such as fuel, or chemicals with medicinal applications. Inscripta has raised more than $400 million in venture capital funding from investors such as Fidelity Management, T. Rowe Price, and D1 Capital Partners. A company spokesperson declined to offer valuation figures following the 2021 funding round.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Inscripta, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Inscripta

Forge green plus iconForge green minus icon

What is Inscripta's IPO price?

The IPO price for Inscripta will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Inscripta?

Inscripta is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Inscripta shares pre-IPO?

If you own Inscripta pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Inscripta a publicly traded company?

Inscripta is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Inscripta's funding to date?

Inscripta has raised $459.69MM to date.
Forge green plus iconForge green minus icon

When was Inscripta founded?

Inscripta was founded in 2015.

Who are Inscripta's major investors?

D1 Capital Partners
Durable Capital Partners
Paladin Capital Group
Foresite Capital

Inscripta funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation

Series E

$150MM raised $XXX.XX $XXX.XX

Series D

$175MM raised $XXX.XX $XXX.XX

Series C-1

$50MM raised $XXX.XX $XXX.XX

Series C

$55.5MM raised $XXX.XX $XXX.XX

Series B

$23.15MM raised $XXX.XX $XXX.XX

Series A

$6.04MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jun 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.